PT2820138T - Retroviral transduction using poloxamers - Google Patents

Retroviral transduction using poloxamers

Info

Publication number
PT2820138T
PT2820138T PT137062832T PT13706283T PT2820138T PT 2820138 T PT2820138 T PT 2820138T PT 137062832 T PT137062832 T PT 137062832T PT 13706283 T PT13706283 T PT 13706283T PT 2820138 T PT2820138 T PT 2820138T
Authority
PT
Portugal
Prior art keywords
poloxamers
retroviral transduction
retroviral
transduction
Prior art date
Application number
PT137062832T
Other languages
Portuguese (pt)
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh
Sirion Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47750713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2820138(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh, Sirion Biotech Gmbh filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh
Publication of PT2820138T publication Critical patent/PT2820138T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/867Retroviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10041Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10041Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PT137062832T 2012-02-29 2013-02-28 Retroviral transduction using poloxamers PT2820138T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12157461 2012-02-29

Publications (1)

Publication Number Publication Date
PT2820138T true PT2820138T (en) 2020-12-24

Family

ID=47750713

Family Applications (2)

Application Number Title Priority Date Filing Date
PT201884889T PT3763820T (en) 2012-02-29 2013-02-28 Retroviral transduction using poloxamers
PT137062832T PT2820138T (en) 2012-02-29 2013-02-28 Retroviral transduction using poloxamers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT201884889T PT3763820T (en) 2012-02-29 2013-02-28 Retroviral transduction using poloxamers

Country Status (9)

Country Link
US (4) US9771599B2 (en)
EP (4) EP3763820B1 (en)
JP (2) JP6290106B2 (en)
DK (2) DK3763820T3 (en)
ES (2) ES2905250T3 (en)
IL (1) IL265014B (en)
PL (2) PL3763820T3 (en)
PT (2) PT3763820T (en)
WO (1) WO2013127964A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763820B1 (en) 2012-02-29 2021-12-22 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Retroviral transduction using poloxamers
JP6412579B2 (en) * 2014-01-10 2018-10-24 シリオン・バイオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Pseudotype lentiviral vector
JP6754761B2 (en) 2014-07-11 2020-09-16 セルジーン コーポレイション How to improve the efficiency of vector introduction into T lymphocytes
TWI735418B (en) 2014-11-05 2021-08-11 美商奇諾治療有限公司 Methods for transduction and cell processing
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
RU2021103425A (en) * 2016-02-12 2021-02-25 Блубёрд Био, Инк. COMPOSITIONS INCREASING THE NUMBER OF VECTOR COPIES (VECTOR COPIES) AND METHODS OF THEIR APPLICATION
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
JP7108551B2 (en) * 2016-03-19 2022-07-28 エクスマ バイオテック コーポレイション Methods and compositions for transducing lymphocytes and their controlled increase
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2018148502A1 (en) * 2017-02-10 2018-08-16 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
CN113631703A (en) * 2018-12-04 2021-11-09 西瑞恩生物科技股份有限公司 Viral transduction using poloxamine
CN114450412A (en) * 2019-06-05 2022-05-06 奥查德疗法(欧洲)有限公司 Compositions and methods for modifying eukaryotic cells
EP3766981A1 (en) 2019-07-18 2021-01-20 OZ Biosciences Cationic poloxamers and their use in transduction
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
EP4045666A4 (en) * 2019-10-16 2023-11-15 Orchard Therapeutics (Europe) Limited Compositions and methods for modifying eukaryotic cells
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
WO2023022090A1 (en) * 2021-08-17 2023-02-23 慶應義塾 Method for producing gene-modified t cell population
CN113980917A (en) * 2021-12-27 2022-01-28 苏州博腾生物制药有限公司 Lentiviral lysis buffer solution and application thereof
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
WO2024033802A2 (en) 2022-08-11 2024-02-15 Fondazione Telethon Ets Gene therapy
WO2024079644A1 (en) 2022-10-11 2024-04-18 Fondazione Telethon Ets 3d cell culture methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
WO2001065911A2 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
WO2006086775A2 (en) * 2005-02-11 2006-08-17 Duke University Methods and compositions for reducing systemic toxicity of vectors
EP3763820B1 (en) 2012-02-29 2021-12-22 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Retroviral transduction using poloxamers
WO2018148502A1 (en) 2017-02-10 2018-08-16 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same

Also Published As

Publication number Publication date
JP2015511483A (en) 2015-04-20
US9771599B2 (en) 2017-09-26
DK3763820T3 (en) 2022-02-07
EP2820138B1 (en) 2020-10-28
PL3763820T3 (en) 2022-03-28
PT3763820T (en) 2022-02-03
WO2013127964A1 (en) 2013-09-06
EP3763820B1 (en) 2021-12-22
EP3763820A1 (en) 2021-01-13
ES2837799T3 (en) 2021-07-01
PL2820138T3 (en) 2021-04-06
EP4151738A1 (en) 2023-03-22
IL265014B (en) 2020-10-29
US11591617B2 (en) 2023-02-28
US10815498B2 (en) 2020-10-27
US20180016600A1 (en) 2018-01-18
DK2820138T3 (en) 2020-12-07
JP6638004B2 (en) 2020-01-29
US20210010026A1 (en) 2021-01-14
US20150064788A1 (en) 2015-03-05
JP6290106B2 (en) 2018-03-07
EP3868888A1 (en) 2021-08-25
JP2018102304A (en) 2018-07-05
US20230130635A1 (en) 2023-04-27
ES2905250T3 (en) 2022-04-07
EP2820138A1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
IL265014B (en) Retroviral transduction using poloxamers
HK1215277A1 (en) Aav variant aav
GB201213700D0 (en) Receptor antagnists II
GB201217807D0 (en) Location-assisted beamforming
EP2918380A4 (en) Razor
EP2918383A4 (en) Razor
EP2873453A4 (en) Stirrer
EP2940784A4 (en) Mode converter
GB201216800D0 (en) Novel use
ZA201409034B (en) Catalysts
EP2940852A4 (en) Converter
HK1189639A1 (en) Planking arrangement
EP2906215A4 (en) Combinations
KR101410945B9 (en) Mixer
IL233440A0 (en) Stand mixers
GB2504611B (en) Fastened Structure
EP2913931A4 (en) Converter
GB201223053D0 (en) Receptor
ZA201502340B (en) Innovation management
GB201220535D0 (en) Mixer
GB201201720D0 (en) Novel combinations
GB201217324D0 (en) Detachable rollabrush
GB201219692D0 (en) Lightweight beaters
GB201214032D0 (en) Concept sixteen
GB201215542D0 (en) Securing means